Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus PD-1/PD-L1 inhibitors after PD-1/PD-L1 failure in advanced NSCLC (non-interventional registry)
ChiCTR2300069510Phase 4Not yet recruiting
- Sponsor
- Lankao County First Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Lankao County First Hospital. Primary endpoint: Disease remission rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300069510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069510.